Showing results (171-180 of 390) with videos related to

Sort By:
Pageof 39
Journal of Comparative Effectiveness Research|July 29, 2023
Handling related publications reporting real-world evidence in network meta-analysis: a case study in multiple sclerosisMarissa Betts, Kyle Fahrbach, Binod Neupane, et al.
International Journal of MS Care|January 17, 2022
Characterizing Long-term Disability Progression and Employment in NARCOMS Registry Participants with Multiple Sclerosis Taking Dimethyl FumarateAmber Salter, Samantha Lancia, Gary Cutter, et al.
Multiple Sclerosis and Related Disorders|December 3, 2022
The nine hole peg test as an outcome measure in progressive MS trialsMarcus W Koch, Pavle Repovic, Jop Mostert, et al.
JAMA Neurology|October 20, 2025
Seizure Frequency Trends Over Time in Treatment-Resistant Focal EpilepsyOjas Potnis, Gabriel Biondo, Rachel Sukonik, et al.
Translational Behavioral Medicine|November 28, 2012
Adopting an Evidence-Based Lifestyle Physical Activity Program: Dissemination Study Design and MethodsAndrea L Dunn, David B Buller, James W Dearing, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 24, 2014
A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosisRuth Ann Marrie, Nadia Reider, Jeffrey Cohen, et al.
Multiple Sclerosis and Related Disorders|January 29, 2019
Validation of the SymptoMScreen with performance-based or clinician-assessed outcomesKathryn C Fitzgerald, Amber Salter, Tuula Tyry, et al.
Archives of Neurology|December 17, 2003
Atrophy is detectable within a 3-month period in untreated patients with active relapsing remitting multiple sclerosisMartin Hardmeier, Stefan Wagenpfeil, Peter Freitag, et al.
Neurology|June 6, 2014
Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS StudyPaul O'Connor, Andrew Goodman, Ludwig Kappos, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 13, 2014
Factors associated with clinically significant increased walking time in multiple sclerosis: results of a survival analysis of short-term follow-up data from a clinical databaseDeborah M Miller, Nicolas R Thompson, Jeffrey A Cohen, et al.
Pageof 39